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Abstract
Background: Patients on warfarin therapy undergo invasive and expensive checks for the coagulability of their blood. No
information on coagulation levels is currently available between two controls.
Methodology: A method was developed to determine warfarin in oral fluid by HPLC and fluorimetric detection. The
chromatographic separation was performed at room temperature on a C-18 reversed-phase column, 65% PBS and 35%
methanol mobile phase, flow rate 0.7 mL/min, injection volume 25 mL, excitation wavelength 310 nm, emission wavelength
400 nm.
Findings: The method was free from interference and matrix effect, linear in the range 0.2–100 ng/mL, with a detection
limit of 0.2 ng/mL. Its coefficient of variation was ,3% for intra-day measurements and ,5% for inter-day measurements.
The average concentration of warfarin in the oral fluid of 50 patients was 2.561.6 ng/mL (range 0.8–7.6 ng/mL). Dosage
was not correlated to INR (r=20.03, p=0.85) but positively correlated to warfarin concentration in the oral fluid (r=0.39,
p=0.006). The correlation between warfarin concentration and pH in the oral fluid (r=0.37, p=0.009) confirmed the
importance of pH in regulating the drug transfer from blood. A correlation between warfarin concentration in the oral fluid
and INR was only found in samples with pH values $7.2 (r=0.84, p=0.004).
Conclusions: Warfarin diffuses from blood to oral fluid. The method allows to measure its concentration in this matrix and
to analyze correlations with INR and other parameters.
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Introduction
Oral anticoagulants are used when an accurate control of
coagulation is required, for example in conditions such as
pulmonary embolism and atrial fibrillation. Warfarin, the most
common anticoagulant [1], has a narrow therapeutic index [2]
and is prone to interference from diet and other drugs [3–6]. For
these reasons, blood coagulability requires frequent monitoring,
typically every day when treatment is started, then once every two
weeks or once a month when a stable dose-response relationship
has been obtained [7-8].
A main problem arising from the adoption of the International
Normalized Ratio (INR) as the standard coagulation assay [9] is the
social and economic cost relating to the frequent access of patients to
laboratories and anticoagulation clinics. The introduction of
instruments that enable patients to monitor INR values from a
blood drop at home represents a first step towards a solution. Studies
suggest that home monitoring with the remote supervision by a
physician or an anticoagulation service can improve the accuracy of
anticoagulation control and prevent adverse events [10–14].
Therapeutic drug monitoring in oral fluid is not a new concept
[15–17] however no study has been published to our knowledge
concerning warfarin or other anticoagulants. Several mechanisms
have been identified for the transfer of analytes from blood to oral
fluid, whose efficiency is reflected by the oral fluid to plasma
concentration ratio (OF/P ratio) [18-19]. Factors such as
molecular weight, protein binding (,99% of warfarin in plasma
is bound to albumin [20]), elimination kinetics, solubility in water
and/or lipids may influence this ratio. In the case of ionizable
drugs, the inclination of the ionic and the neutral form to pass
from the blood to oral fluid may be drastically different. For this
reason, the pH values of these fluids are key factors for
determining equilibria and transfer rates. A theoretical OF/P
(oral fluid to plasma) concentration ratio can be estimated from the
Rasmussen equation [21].
The concentration of a drug in oral fluid essentially represents
the free nonionized fraction of the drug in plasma, which is the
pharmacologically active fraction. Thus, an analysis of oral fluid
has the potential for minimally invasive monitoring of the active
fraction of drugs in a far less complex chemical matrix than blood.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28182In this work a method to determine the concentration of warfarin
in oral fluid is presented. This method was also successfully applied
to a few sweat samples (Fig. S1). The concentration of the drug
and pH were measured in the oral fluid samples collected from 50
patients and their correlations to INR and dose were evaluated.
Materials and Methods
Ethics statement
Ethical permission was obtained from the Ethics Committee of
the Azienda Ospedaliero-Universitaria Pisana. All patients and
nominally healthy subjects who volunteered to join the project
gave written informed consent prior to their participation.
Study subjects
Fifty adults (27 males, 23 females) on warfarin therapy were
recruited.Patients with hepaticor kidney pathologieswereexcluded
from the study. The enrolled subjects were treated for atrial
fibrillation (AF, 62%), deep vein thrombosis (DVT, 12%),
pulmonary embolism (PE, 10%), as mechanical or biological heart
valve bearers (MHV, 10%) or for other reasons (6%). Their mean
age was 7469 years (range, 42–88 years) and they were on an
average warfarin dose of 27613 mg/week (range, 5–57.5 mg/
week). INR values varied from 1.2 to 3.8, with an average value of
2.360.6. Approximately three fifths of the patients (31) had INR
values within the recommended range for anticoagulation (2.0–3.0).
The Mann-Witney test did not highlight statistically significant
gender differences (p,0.05) for any of the above parameters. Ten
nominally healthy subjects who were not taking any drugs also
contributed to the project by providing control samples.
Chemical reagents
Warfarin, i.e. 3-(a-acetonylbenzyl)-4-hydroxycoumarin sodium
salt (purity $98%), sodium phosphate monobasic (purity
$99.0%), potassium phosphate dibasic (purity $99.0%) and
high-performance liquid chromatography (HPLC) grade methanol
were purchased from Sigma Aldrich. HPLC grade water was
produced by a Milli-Q Reagent Water System (Millipore, USA).
The thromboplastin reagent (HemosIL RecombiPlasTin 2G),
thromboplastin diluent (HemosIL RecombiPlasTin 2G Diluent),
calibration plasma, normal control assay, low and high abnormal
control assays used for INR measurements and quality control
were supplied from the Instrumentation Laboratory (Milan, Italy).
A stock solution (1 M, pH 7.02) was prepared by dissolving
sodium phosphate monobasic and potassium phosphate dibasic in
water. This solution was then diluted to 25 mM to obtain the
phosphate buffer solution (PBS) used for HPLC analyses.
A 1 mg/mL stock solution of warfarin was prepared by
dissolving the weighed pure compound in water and then diluted
with PBS to prepare a 10 mg/mL standard solution. This solution
was further diluted with PBS to achieve 0.5, 1, 2, 5, 10, 20, 50 and
100 ng/mL standard working solutions of warfarin.
Instrumentation
High performance liquid chromatography was carried out by a
Jasco HPLC system equipped with an autosampler (AS 2055), a
quaternary low pressure gradient pump (PU 2089) and a spectro-
fluorimetric detector (FP 2020). The column temperature was
controlled by a thermostat (HT 3000, ClinLab). The HPLC system
was controlled by ChromNAV
TM software from Jasco. To validate
the analytical method, a few selected samples were also analyzed by
a Micro HPLC system (Perkin Elmer Series 200) coupled with an
autosampler (Series 200) and a triple quadrupole mass spectrometer
(Applied Biosystems Sciex API 365) operating in the Selected
Reaction Monitoring (SRM) mode. The mass spectrometer was
equipped with an Atmospheric Pressure Photo-Ionization (APPI)
interface operating in negative ion mode. The INR measurements
were carried out by an automatic system (ACL TOP700,
Instrumentation Laboratory) equipped with an autosampler. Data
processing was performed by Prism 5 (GraphPad Software Inc.).
Experimental conditions
Chromatographic separation by the Jasco HPLC system was
carried out in isocratic conditions with two different columns:
– a C-18 reversed-phase column Chromspher 5 PAH, Varian,
15064.6 mm, 5 mm, coupled with a guard column ChromSep
SS 1062 mm, Varian, a 72% PBS and 28% methanol mobile
phase at a flow rate of 1.0 mL/min; injection volume 25 mL,
temperature 25uC;
– a C-18 reversed-phase column Poroshell 120 EC-C18, Agilent
Technologies, 10064.6 mm, 2.7 mm connected to a guard
column TC - C18, 12.564.6 mm, 5 mm, Agilent Technologies,
with a 65% PBS and 35% methanol mobile phase at a flow rate
of 0.7 mL/min, injection volume 25 mL, temperature 25uC.
Spectrofluorimetric measurements were performed at an
excitation wavelength of 310 nm and an emission wavelength of
400 nm. The total run time was 15 minutes.
Chromatographic separation by the Perkin Elmer HPLC system
was carried out in isocratic conditions on a C-18 reversed-phase
column Chromspher 5 PAH, Varian, 15064.6 mm, 5 mm,
coupled with a guard column ChromSep SS 1062 mm, Varian.
A 50% acetonitrile, 50% water containing 0.1% formic acid
mobile phase was used at a flow rate of 1 mL/min at 25uC. The
injection volume was 25 mL. Warfarin was quantified by the mass
spectrometric detector observing the following two ion transitions
(expressed by their mass number/charge number ratios): m/z
307R161 and m/z 307R250.
Spectrometric INR measurements were carried out at a
wavelength of 671 nm to minimize optical interference (e.g.
hemoglobin and bilirubin). The quality control procedure for INR
measurements consisted in analysing three reference samples
(normal, low and high INR levels) provided by the Instrumenta-
tion Laboratory at least once every eight hours. A coefficient of
variation ,1% for measurements performed on the same day and
,3% for measurements performed on different days demonstrated
the good repeatability of the method.
Sample collection and preparation
Roll-shaped biocompatible synthetic swabs (SalivetteH Cortisol,
Sarstedt) were delivered to the study subjects to be kept in the
mouth for 5 min. Oral fluid was then recovered by centrifugation
of the swabs at 3000 rpm for 5 min, filtered by 0.2 mm syringe
filters (Spartan, Whatman) and stored at 4uC until assay. Before
storage, the pH value was measured by narrow range (resolution
0.3 pH units) pH paper strips (Pehanon, Macherey Nagel).
All samples were collected at the same time (8.30–10.00 AM) to
avoid any effects due to possible circadian variations. Patients
generally take warfarin in the late afternoon, therefore it can be
assumed that the last dose had been completely absorbed when
samples were collected.
Pooled patient oral fluid samples (POFSs) were obtained by
pooling samples from 20 patients. Control oral fluid samples
(COFSs) were obtained from 10 volunteers who stated that they
were not taking warfarin. Aliquots of COFS were spiked with
known amounts of warfarin to obtain standard oral fluid samples
(SOFSs) at different concentration levels.
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Method validation
Figure 1 shows the HPLC chromatograms of a warfarin
standard solution, a COFS, a SOFS and a POFS. The standard
solution, the SOFS and the POFS had approximately the same
warfarin concentrations. The warfarin peaks had a symmetric
shape and were well separated from the other chromatographic
signals. In the experimental conditions reported in the caption, the
retention time (tR) was 10.2 min with a standard deviation of
0.1 min in five replicate measurements. PBS blanks, standard
working solutions and SOFSs were randomly included within the
sequences of analyses of patients’ samples for quality control. The
method validation included the evaluation of interferences, matrix
effect, calibration curve, limit of detection (LOD), intra-day and
inter-day precision, stability and recovery.
Interference
The possible presence of interfering endogenous substances was
investigated by comparing the warfarin concentration determined
in a standard solution containing 5.0 ng/mL, a SOFS with a
spiked concentration of 5.0 ng/mL and two POFSs with unknown
concentrations. The samples were analyzed in triplicate, by
HPLC-Fluorimetry with both columns (i.e. Chromspher 5 PAH
and Poroshell 120 EC-C18) and by HPLC-MS/MS. As already
stated, the latter technique was only used to confirm and validate
the results of the former.
Table 1 shows the warfarin mean concentration and the
coefficient of variation for all the samples. These results
highlighted a very good agreement between the various methods
in the case of the standard solution and the SOFS, both with an
expected value of 5.0 ng/mL. The difference between the
concentrations measured with HPLC-MS/MS and HPLC-Fluo-
rimetry was about 10%. The situation was quite different for the
two samples collected from patients under oral anticoagulant
therapy. The concentration values obtained by the HPLC-MS/
MS, which were assumed as reference values, and by the HPLC-
Fluorimetry with Poroshell 120 EC-C18 were in good agreement
(+9% for POFS-1 and +12% for POFS-2), whereas the values
obtained by the HPLC-Fluorimetry with Chromspher 5 PAH
column were much higher (+40% for POFS-1 and +76% for
POFS-2). The interference, which was only present in the patients’
samples, may result from the presence of a warfarin metabolite
[22]. On the basis of these results, the Poroshell 120 EC-C18
column was used in the subsequent evaluations of the performance
of the method and in the clinical study.
Matrix effect
The evidence that the shape and position of the warfarin peaks
were not affected by the presence of the oral fluid matrix (Fig. 1)
suggested the absence of any notable matrix effect. This hypothesis
was confirmed by the limited difference of the slopes of the
calibration curves obtained in the 1–10 ng/mL concentration
range for a set of standard solutions and a set of spiked POFSs,
which were 19380660 and 194006300, respectively. The slopes
Figure 1. HPLC chromatograms of: A) a standard working
solution with a warfarin concentration of 1.5 ng/mL; B) a
control oral fluid sample (COFS); C) a standard oral fluid
sample (SOFS) with a warfarin concentration of 1.4 ng/mL; D) a
patient oral fluid sample (POFS) with a warfarin concentration
of 1.4 ng/mL. (Chromatographic conditions: Poroshell 120 EC-C18
column, 65% PBS and 35% methanol mobile phase, flow rate of 0.7 mL/
min; injection volume 25 mL).
doi:10.1371/journal.pone.0028182.g001
Table 1. Comparative determination of warfarin in a standard solution, SOFS and POFS by HPLC-Fluorimetry with both columns
(Chromspher 5 PAH and Poroshell 120 EC-C18) and by HPLC-MS/MS.
Sample Warfarin mean concentration (n=3), ng/mL (CV%)
Expected value HPLC-Fluo (Poroshell) HPLC-Fluo (Chromspher) HPLC-MS/MS
Standard solution 5.0 4.6 (5%) 4.9 (3%) 5.2 (3%)
SOFS 5.0 5.3 (6%) 5.0 (4%) 4.9 (4%)
POFS-1 unknown 3.5 (6%) 4.5 (5%) 3.2 (7%)
POFS-2 unknown 7.1 (4%) 11.1 (4%) 6.3 (6%)
doi:10.1371/journal.pone.0028182.t001
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difference resulted not significant (P=0.87, two-tailed).
Calibration curve
The warfarin peak area linearly increased with the warfarin
concentration of standard working solutions in the observed
concentration range 0.5–100 ng/mL. According to Deming
regression analysis, the best fit model was: y=(19380660) x,
(R
2=0.9999, standard deviation of residuals sy.x=1000 AU).
Limit of detection
A SOFS at about 0.5 ng/mL was prepared and assumed as
‘‘blank’’ or the closest concentration to the limit of detection. This
sample was analyzed five times and the corresponding standard
deviation (sb) was 0.07 ng/mL. According to the IUPAC definition
[23], the LOD was evaluated as three times the standard deviation
sb of the ‘‘blank’’, which corresponds to about 0.2 ng/mL.
Precision
Within-run repeatability was estimated in SOFSs with a
warfarin concentration of 1.0, 5.2 and 10.1 ng/mL. The
correspondent relative standard deviations obtained in 6 replicate
measurements were 6, 4 and 2% respectively. A total standard
deviation of 8% was estimated in a SOFS with a warfarin
concentration of 2.9 ng/ml which was analyzed 30 times in six
weeks.
Recovery and stability
The recovery percentage of warfarin from the sampling swabs
was estimated at three pH levels (6, 6.9, 7.5) covering the range of
variability observed in the oral fluid samples. Three SOFSs with a
warfarin concentration of about 5 ng/mL, a volume of 4 mL and
an initial pH value of 6.9 were used for the experiments. One was
acidified to pH 6 by adding 10 mL of phosphoric acid 1 M,
another was alkalinized to pH 7.5 by adding 8 mL of sodium
hydroxide 1 M. Each of these three samples was divided into four
aliquots. The first aliquot was analyzed without any further
treatment, the other three were absorbed into the synthetic swabs
and treated as normal samples. The recovery percentage was then
calculated from the ratio between the average warfarin concen-
tration in the samples recovered from the swab and the initial
concentration. The recovery percentage of the filtration step was
estimated in the same way.
The recovery of warfarin from the sampling swabs was
satisfactory. No dependence on pH was found, with recovery
percentages equal to 9960.1% at pH 6 and 10060.1% at pH 6.9
and 7.5. Experiments performed to assess warfarin recovery
during the filtration step showed a value of 9962% at a
concentration level of 5 ng/mL.
The stability in time of the treated samples (i.e. centrifuged and
filtrated) was assessed in aliquots of POFS during a one and half
month storage at 4uC. No significant degradation occurred.
Clinical Study
The average concentration of warfarin in the oral fluid was
2.561.6 ng/mL, with values ranging from 0.8 to 7.6 ng/mL,
whereas the pH of the oral fluid was 6.760.4 in the range 6.0–7.5
(Fig. S2).
Principal component analysis [24-25] was used to obtain an
overall view of the internal structure of the data (Fig. 2). The
principal component analysis produces two plots in which similar
items are located close to one another: the score plot (Fig. 2A)
shows the relationships between the objects, and the loadings plot
(Fig. 2B) shows the correlation between the variables. If the two
plots are superimposed, the objects characterized by a high value
of a variable will be located close to this variable. In our case, the
score plot shows that the majority of patients with INR values
above the recommended range for anticoagulation form a separate
group in the upper left corner. The positions of the variables in the
loadings plot suggest that most patients with high INR values are
taking doses of warfarin and have similar concentrations of
warfarin in the oral fluid to patients with INR in the
recommended therapeutic range. The main exception is patient
P9, who falls in the upper right corner for taking high doses of
warfarin and shows very high concentrations of the drug in the
oral fluid. The loadings plot also suggests the existence of a positive
correlation between dose and warfarin concentration in the oral
fluid as well as a negative correlation between INR and pH values.
Figure 3 reports INR and warfarin concentration values in oral
fluid versus weekly dose. No correlation was found between INR
values and dose (r=20.03, p=0.85, Fig. 3A), whereas there was a
clear positive correlation between warfarin concentration in the
oral fluid and dose (r=0.39, p=0.006, Fig. 3B).
The first result reflects the wide variability of patient responses
to the drug observed in over fifty years of clinical use. This
variability has been ascribed to factors such as gastrointestinal
Figure 2. Principal component analysis of patient data. A) score
plot, B) loadings plot. Legend: pH of the oral fluid (pH), warfarin
concentration in the oral fluid (WC), warfarin dose (Dose), INR.
doi:10.1371/journal.pone.0028182.g002
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diet, alcohol consumption, smoking etc.) [6,26]. The concomitant
assumption of other drugs can change the fraction of warfarin
bound to plasma proteins and influence its pharmacokinetics and
pharmacodynamics. Genetic variability in the cytochrome P450
(for specific CYP isoforms) has also been identified as a further key
factor [27–29].
The correlation between warfarin concentration in oral fluid
and dosage is also not surprising. Warfarin concentration in oral
fluid is expected to mirror (if the pH level in the oral fluid is not
much lower than plasma pH) the concentration of free warfarin in
plasma, and to be highly correlated to the total warfarin
concentration in plasma. The ratio between the concentrations
of bound and unbound warfarin in plasma, in fact, is reported to
be generally subject to only minor variations (between 0.01 and
0.03), with the exception of the concomitant assumption of other
drugs capable of displacing bound warfarin from albumin [30].
Obviously, the degree of correlation between warfarin concentra-
tion in oral fluid and dosage cannot be higher than the correlation
existing between warfarin concentration in plasma and dosage. A
correlation coefficient of r=0.,55 was found by Lombardi et al.
[31] between total warfarin concentration in plasma and weekly
dosage, whereas Huang et al. [32] found a correlation coefficient
of 0.378 between the concentration of free warfarin in plasma and
weekly dosage. Our value is compatible with these results.
A correlation was found between the concentration of warfarin
in the oral fluid and the pH value (r=0.37, p=0.009) (Fig. 4). We
believe that this correlation may be due to a hindered warfarin
transfer from plasma when pH values of the oral fluid approach
the pKa of warfarin (5.19). In fact the lowest warfarin
concentration levels in oral fluid were observed in the most acidic
samples. Two patients, with pH values of oral fluid lower than 6,
had to be excluded from the study because the warfarin
concentration in the oral fluid was below the quantification limit.
Figure 5A reports the warfarin concentration in oral fluid versus
INR. No correlation was found between these two parameters
(r=20.11, p=0.43). However, if only the samples with pH values
equal or higher than 7.2 were considered, a correlation between
these two parameters was observed (r=0.84, p=0.004, Fig. 5B).
Although the limited number of patients does not enable a firm
conclusion to be drawn on this point, the result is compatible with
the hypothesis that there is a good correlation between the free
warfarin concentration in plasma and INR, which is only mirrored
in the oral fluid when its pH value enables the drug to be
transferred from the blood.
Huang et al. [32] found a modest but significant correlation
between free warfarin in plasma and INR (r=0.207, p=0.03), as
did Lombardi et al. [31] who found a similar correlation between
total warfarin in plasma and INR (r=0.25, p=0.079). In
comparison with these studies, our set of patients showed a lower
correlation between warfarin concentration in oral fluid and INR
when the pH of oral fluid was lower than plasma pH, however
they showed a higher correlation when these pH values were in the
same range. This suggests that when pH conditions lead to an
optimal diffusion from blood, the warfarin assayed in the oral fluid
may reflect the pharmacodynamics more precisely, thus maybe
overcoming the effect of an unknown confounding factor
connected to the complex chemical nature of blood. To confirm
this second hypothesis, we used measured pH values to calculate
the theoretical warfarin concentration values in plasma by the
Rasmussen equation (Fig. 6) [21]. The use of the pH information
resulted in an increased correlation (r=0.91, p=0.0006).
In summary, we have presented a method for analysing
warfarin in oral fluid which highlights the presence of the drug
in both oral fluid and sweat at concentration levels of a few ng/
mL. The value of pH in oral fluid is likely to play an important
role in determining the transfer of the drug from blood. The
correlation between the concentration of warfarin in the oral fluid
Figure 3. Effect of the warfarin weekly dose on A) INR and B)
warfarin concentration in oral fluid.
doi:10.1371/journal.pone.0028182.g003
Figure 4. Correlation between the concentration of warfarin
and pH in the oral fluid.
doi:10.1371/journal.pone.0028182.g004
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concentrations in plasma and INR reported in previous studies.
However, we found a much higher correlation between oral fluid
warfarin and INR in patients with an oral fluid pH above 7.2,
which might be of a potential clinical interest. When the
Rasmussen equation was used to estimate the plasma warfarin
concentration in this group of patients, the resulting correlation
with INR values increased significantly.
The variability of the oral fluid pH within the same individual
over time and among different individuals, its role in determining
the warfarin transfer rates and the possibility of using its value to
predict warfarin concentrations in blood need to be clarified prior
to any clinical application. The determination of warfarin
concentration in oral fluid could become a noninvasive test
enabling the efficacy and safety of the therapy to be monitored in
the time span between two conventional INR tests. In fact, due to
the 72-hour delay in the biological action of warfarin, an increase
in concentration in oral fluid could be an early signal of risk of
hemorrhagic event. Such tests could be particularly useful in
patients with high levels of anticoagulation or undergoing a
combined anticoagulation/antiaggregation treatment.
Supporting Information
Figure S1 Chromatograms of representative sweat
samples. A) a blank sweat sample from a volunteer not taking
the drug; B) a patient sweat sample with an estimated warfarin
concentration of about 4 ng/mL (tr=10.2 min).
(TIF)
Figure S2 Distribution of pH values in patient oral fluid
samples.
(TIF)
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